Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.

Vaccitech, a UK-based developer of vaccines for infectious diseases and cancer spun out of University of Oxford, filed for an initial public offering in the US on Friday. Financial terms have not yet been set and Vaccitech has used a placeholder $100m target in its draft prospectus. The spinout is looking to list on the…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.